COSTAL CHONDROCYTE-DERIVED PELLET-TYPE AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR TREATMENT OF ARTICULAR CARTILAGE DEFECT: A RANDOMIZED PHASE 3 CLINICAL TRIAL COMPARED TO MICROFRACTURE
Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) gr...
Saved in:
Published in | Cytotherapy (Oxford, England) Vol. 26; no. 6; p. e3 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee.
Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes.
Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed.
Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes.
<!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –> |
---|---|
AbstractList | Background & AimObjective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Methods, Results & ConclusionDesign A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed. Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes. <!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –> Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed. Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes. <!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –> |
Author | Park, J. Lee, J. Yoon, K. Lee, S. |
Author_xml | – sequence: 1 givenname: J. surname: Lee fullname: Lee, J. organization: R&D iInstitute, Bio Solution Co, Ltd, Seoul, Korea (the Republic of) – sequence: 2 givenname: S. surname: Lee fullname: Lee, S. organization: R&D iInstitute, Bio Solution Co, Ltd, Seoul, Korea (the Republic of) – sequence: 3 givenname: J. surname: Park fullname: Park, J. organization: CHA Bundang Medical Center, Seoul, Please Select, Korea (the Republic of) – sequence: 4 givenname: K. surname: Yoon fullname: Yoon, K. organization: Kyung-Hee University, Seoul, Please Select, Korea (the Republic of) |
BookMark | eNqFUWGL1DAQLXKCd6d_wE_5A12TtE27hwghTW8LbbNkU-H8EmKahda1K-2dsD_M_2fC-UEEFQZmYOa9efPmJrqaz7OLorcIbhBE5N20mezlcYMhTjfQB0peRNcozfMYZ4RchZpkcYLT7avoZl0nCDEsiuw6-sHEQdEGsJ3oSinYg-JxyWX9kZdgz5uGq1g97DmgvRKNuBf94fdRULf7hnaKqlp0oBISKMmpanmngKgAlapmfUMlYKFs6D0HJa84U3eAAkm7UrT1p7BpRw8cJIA1dVczL0fJOogS7Z5K31cCtDWTopKUqV7y19HLozmt7s2vfBv1FVdsF3uJAR9b70Ti7zWDwy4xJkfI2dRtHYEwM8YhbKEZ8iEvSFJk221hPhNXkCGD2BJjMHJHl7vkNsLPvHY5r-vijvrbMn41y0UjqIPxetLBeB2M19AHSjzo_TPIeWXfR7fo1Y5utm4YF2cf9XAe_w3_8AfcnsZ5tOb0xV3cOp2fltnfrJFesYb6ED4bHotTCAlOiCe4-zvB_7b_BDMwqeI |
ContentType | Journal Article |
Copyright | 2024 |
Copyright_xml | – notice: 2024 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.jcyt.2024.04.013 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1477-2566 |
EndPage | e3 |
ExternalDocumentID | 10_1016_j_jcyt_2024_04_013 S1465324924006236 1_s2_0_S1465324924006236 |
GroupedDBID | --- --M .1- .FO .~1 1P~ 1~. 29F 36B 4.4 457 4G. 53G 5GY 5VS 7-5 8P~ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AATTM AAXKI AAXUO AAYWO ABDBF ABGSF ABJNI ABMAC ABMZM ABUDA ABXDB ACDAQ ACGEJ ACGFS ACIEU ACRLP ACUHS ACVFH ADBBV ADCNI ADCVX ADEZE ADXPE AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFKVX AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGRDE AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AJWEG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AWYRJ AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DU5 EAP EBC EBS EFJIC EFKBS EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA H13 HVGLF HZ~ KOM LUGTX M44 MO0 O-L O9. OAUVE OK~ P-8 P-9 P2P PC. Q38 R2- ROL SDF SPCBC SSH SSI SSU SSZ SV3 T5K TDBHL TFW Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW AAIAV AAYXX AGRNS CITATION |
ID | FETCH-LOGICAL-c2023-32ade2e3aa711ec4e9e6005aae12c0ad7d786385998ab6e86d502c6aa21efe7e3 |
IEDL.DBID | .~1 |
ISSN | 1465-3249 |
IngestDate | Tue Jul 01 03:32:40 EDT 2025 Sat Jun 29 15:31:21 EDT 2024 Sun Feb 23 10:18:43 EST 2025 Tue Aug 26 16:48:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | clinical trial autologous chondrocyte cartilage regeneration |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2023-32ade2e3aa711ec4e9e6005aae12c0ad7d786385998ab6e86d502c6aa21efe7e3 |
ParticipantIDs | crossref_primary_10_1016_j_jcyt_2024_04_013 elsevier_sciencedirect_doi_10_1016_j_jcyt_2024_04_013 elsevier_clinicalkeyesjournals_1_s2_0_S1465324924006236 elsevier_clinicalkey_doi_10_1016_j_jcyt_2024_04_013 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2024 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: June 2024 |
PublicationDecade | 2020 |
PublicationTitle | Cytotherapy (Oxford, England) |
PublicationYear | 2024 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0020885 |
Score | 2.384561 |
Snippet | Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx)... Background & AimObjective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with... |
SourceID | crossref elsevier |
SourceType | Index Database Publisher |
StartPage | e3 |
SubjectTerms | Advanced Basic Science autologous chondrocyte cartilage regeneration clinical trial Other |
Title | COSTAL CHONDROCYTE-DERIVED PELLET-TYPE AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR TREATMENT OF ARTICULAR CARTILAGE DEFECT: A RANDOMIZED PHASE 3 CLINICAL TRIAL COMPARED TO MICROFRACTURE |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1465324924006236 https://www.clinicalkey.es/playcontent/1-s2.0-S1465324924006236 https://dx.doi.org/10.1016/j.jcyt.2024.04.013 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqcuGCeIqlUPmAeqFhYzuPhZuVOGwgm0RZL2q5WI7jSu1hqdhy2Av_iv_HeJO0RVQgIeWQh8e2POPxjDPzGaHXAfUZs8z3TGRaLzC082aaMC8yDJyJOIrPrEsUXpTRfBV8PAlP9lAy5sK4sMpB9_c6faethzfTYTSnl-fn0yVx0GAO8C5wiYDMwW4HUDvI9Nsf12EeFGZR2GcYhZ4rPSTO9DFeF2br4ilpsIM7JezuxenWgpM9RA8GSxHzvjOP0J5dP0ZHdQ81vT3G8iZzanOMj3B9A0K9fYJ-JtVS8gIn86pMmyo5lcJLwWn7LFJci6IQ0pOntcAgn-5XUrVa3i6K80Vd8FLuNrAwOIpYNoJLB_yPqwyDEZwnq4I3OHG3Bf8gcCoykcj3mOOGl2m1yL-4luZ8KTDDSZGXDngBqsldp6pFzRv4LisMYtBUWcMTF3_xFK0yIZO5NxzR4Bl37jqMqO4stUzrmBBrAvvOggUVam0JNb7u4i6ewQwPwanTbWRnURf61ERaU2LPbGzZM7S__rq2zxHWHaFtC-ZpHIQB084RA9fMtKCBjAlZMEFvRt6oyx6JQ40hahfKcVI5TiofLsImiI3sU2OOKWhFBQvFX6niu6jsZpjYG0XUhipf_SF8ExReU_4mv_9o8cV_0h2g--6pD1p7ifavvn23r8A8umoPd_J_iO7x_NO8_AUYcAE0 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbK9gAXxFNsefmAeqHRxnEeCzcr8ZLQvJT1opaL5Tiu1B6Wii2H_WH8P8abpC2iAgkphyjOxJbn4Rln5jNC73zPpdRQ19Ghbh1fe50zV4Q6oaYQTERhdGZsoXBRhunK_3wSnOyheKyFsWmVg-3vbfrOWg9PZsNszi7Pz2dLYqHBLOCdbwsBaXgP7Vt0qmCC9ll2nJbXcRcoUtAXGQWOJRhqZ_o0rwu9tSmVnr9DPCX07vXp1pqzeIQeDs4iZv14HqM9s36CDusebXp7hMVN8dTmCB_i-gaHevsU_YyrpWA5jtOqTJoqPhXcSSBu-8ITXPM858IRpzXHIKL2b1K1Wt5-FWdFnbNS7PawMMSKWDScCYv9j6sFBj84i1c5a3Bsb3P2ieOEL3gsPmKGG1YmVZF9tT2lbMkxxXGelRZ7AT6T2UFVRc0aaBcVBkloqkXDYpuC8QytFlzEqTOc0uBoe_Q6zKjqjGeoUhEhRvvmgwEnKlDKEE-7qou6aA5KHkBcp9rQzMMucD0dKuURc2YiQ5-jyfrb2rxAWHXEa1vwUCNgJFU2FoPoTLdghLQOqD9F70feyMsejEOOWWoX0nJSWk5KFy5Cp4iO7JNjmSkYRglrxV-poruozGbQ7Y0kcuNJV_4hf1MUXFP-JsL_6PHgP-neovupKHIJ7Dt-iR7Ylj6H7RWaXH3_YV6Dt3TVvhm04RcCOgPl |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COSTAL+CHONDROCYTE-DERIVED+PELLET-TYPE+AUTOLOGOUS+CHONDROCYTE+IMPLANTATION+FOR+TREATMENT+OF+ARTICULAR+CARTILAGE+DEFECT%3A+A+RANDOMIZED+PHASE+3+CLINICAL+TRIAL+COMPARED+TO+MICROFRACTURE&rft.jtitle=Cytotherapy+%28Oxford%2C+England%29&rft.au=Lee%2C+J&rft.au=Lee%2C+S&rft.au=Park%2C+J&rft.au=Yoon%2C+K&rft.date=2024-06-01&rft.issn=1465-3249&rft.volume=26&rft.issue=6&rft.spage=e3&rft.epage=e3&rft_id=info:doi/10.1016%2Fj.jcyt.2024.04.013&rft.externalDBID=ECK1-s2.0-S1465324924006236&rft.externalDocID=1_s2_0_S1465324924006236 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14653249%2FS1465324924X00067%2Fcov150h.gif |